# Neurovia Dynamics — Investor Executive Brief

## Investment thesis

Neurovia Dynamics is developing a functional-material platform with two parallel commercialization paths:

1. **Nanofiber applications:** build from existing spun material forms and historical laboratory observations toward application-specific prototypes, validation, paid development, and strategic partnerships.
2. **Conventional thermoplastic manufacturing:** validate whether the functional molecular state survives melt processing, allowing transfer through familiar industrial infrastructure and licensing at scale.

## Why it matters

Bacterial disease represents a major global burden. Neurovia does not claim PhantomFiber can prevent that burden in full. The opportunity is to create fibers, filters, surfaces, and protective systems capable of contributing to biological-risk reduction at the material layer.

## Existing record

- Film and electrospun-fiber material forms have been produced.
- Historical testing reported an R72 value of 8.017 against *E. coli* MG1655, calculated at the assay detection limit; repetition was recommended.
- The same effect was not observed against *P. aeruginosa*.
- EPR evidence supports continued investigation of a radical-associated functional state.
- Air Oasis documented non-binding commercial interest.

## Business model

Paid development, specialty material supply, pilot transfer, manufacturing know-how, field-specific licensing, and royalties. Neurovia does not plan to build a commodity-scale fiber plant.

## Public operating identity

Because the current Neurovia Dynamics corporate page is not controlled by Tim Zlomke, Neurovia Applied Defense serves as the controlled public expression of mission applications and government engagement.